New York, NY -- (SBWIRE) -- 12/20/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Opko Health Inc (NYSE:OPK), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Arena Pharmaceuticals, Inc (NASDAQ:ARNA), XOMA Corp (NASDAQ:XOMA)
Opko Health Inc (NYSE:OPK) the stock opened the session at $8.82 but then moved to $8.81. At that price, the stock showed a negative performance of -0.56%. OPKO Health, Inc. (OPKO) is a multi-national pharmaceutical and diagnostics company. OPKO is developing a range of solutions to diagnose, treat and prevent various conditions, including molecular diagnostics tests, point-of-care tests, and pharmaceuticals and vaccines. Its lead program is a molecular diagnostics platform for the development and commercialization of blood-based tests for conditions.
Will OPK Get Buyers Even After The Recent Rally? Find Out Here
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) opened the session at $0.71 and closed the session at $0.721. The stock showed a negative performance of -2.49% in previous trading session. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Has IMUC Found The Bottom And Ready To Gain Momentum? Find Out Here
Arena Pharmaceuticals, Inc (NASDAQ:ARNA) opened the session at $5.56 and closed the session at $5.60. The stock showed a positive performance of 0.36% in previous trading session. The beta of the stock remained -0.39. Arena Pharmaceuticals, Inc. (Arena) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel,
Why Should Investors Buy ARNA After The Recent Gain? Just Go Here and Find Out
XOMA Corp (NASDAQ:XOMA) the stock advanced 8.43% and finished the session at $6.30. The beta of the stock remained 2.39. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company’s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet,
Will XOMA Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)